Cancer Pain Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

Cancer Pain Treatment Market

(Albany, USA) DelveInsight’s “Cancer Pain Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Cancer Pain, historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. 

The Cancer Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cancer Pain market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Cancer Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cancer Pain market.

Request for a Free Sample Report @ Cancer Pain Market Forecast

Some facts of the Cancer Pain Market Report are:

• According to DelveInsight, Cancer Pain market size is expected to grow at a decent CAGR by 2034.
• In the 7MM, the US accounted for the largest market size of cancer pain with nearly USD 1,680 million in 2023.
• Leading Cancer Pain companies working in the market are Wex Pharma, Sorrento Therapeutics, Tetra Bio-Pharma, Abbvie, Novartis AG, Teva Pharmaceutical, Pfizer Inc, Amneal Pharmaceuticals, Aurobindo Pharma, Johnsons & Johnsons, GSK Plc, Sun Pharmaceutical, Cipla Inc, Ipsen Pharma, Sanofi, Boehringer Ingelheim, Alembic Pharmaceuticals, Lupin, Zydus Group, Apotex Inc, Aurobindo Pharma, Endo Pharmaceuticals plc, Orexo AB, Mundipharma International, Hisamitsu Pharmaceutical and others.
• Key Cancer Pain Therapies expected to launch in the market are Tetrodotoxin, Resiniferatoxin, QIXLEEF, and others.
• In 2021, the total incident cases of cancer pain in the US were ~2,321,000 cases, which are anticipated to increase in 2034.
• On November 12, 2024, AstraZeneca announced the initiation of Phase III trials for AZD0486, a novel therapy aimed at managing pain in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
• On April 27, 2024, Compass Therapeutics received fast-track designation from the FDA for CTX-009, a bispecific antibody targeting DLL4/VEGF-A, for the treatment of previously treated, metastatic, or locally advanced biliary tract cancer.
• On May 17, 2024, GSK announced that the FDA accepted their application for review of dostarlimab-gxly in combination with standard chemotherapy for all adults with primary advanced or recurrent endometrial cancer, including those with mismatch repair-proficient/microsatellite-stable tumors.
• On May 17, 2024, Syros Pharmaceuticals received fast-track designation for tamibarotene, an oral RARα agonist, in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia with RARA overexpression in adults who are older than 75 years or have comorbidities that preclude intensive induction chemotherapy.

Cancer Pain Overview

Cancer pain is a prevalent and distressing symptom experienced by many cancer patients, significantly affecting their quality of life. It arises from various factors, including tumor growth compressing nerves, bones, or organs, as well as from cancer treatments like chemotherapy, radiation, or surgery. The intensity of cancer pain can range from mild discomfort to severe, debilitating agony, and it may be acute, chronic, or episodic (breakthrough pain).

Effective management of cancer pain is critical for improving patient outcomes. Treatment approaches are often multimodal, combining pharmacological options such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and adjuvant therapies (e.g., antidepressants or anticonvulsants) with non-pharmacological methods like physical therapy, psychological support, and relaxation techniques. For localized pain, procedures like nerve blocks or palliative radiation may be employed.

Advancements in personalized medicine have led to targeted therapies that address pain specific to cancer types and stages. However, barriers such as opioid stigma, underreporting of symptoms, and inadequate access to palliative care persist, leading to under-treatment. Addressing these challenges requires a multidisciplinary approach and patient-centered care to ensure optimal pain relief and improved quality of life for individuals battling cancer.

Learn more about Cancer Pain treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cancer Pain Treatment Market

Cancer Pain Market 

The Cancer Pain market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cancer Pain market trends by analyzing the impact of current Cancer Pain therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Cancer Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cancer Pain market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cancer Pain market in 7MM is expected to witness a major change in the study period 2020-2034.

Cancer Pain Epidemiology 

The Cancer Pain epidemiology section provides insights into the historical and current Cancer Pain patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cancer Pain market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Cancer Pain Prevalence and Trends @ Cancer Pain Epidemiology

Cancer Pain Drugs Uptake

This section focuses on the uptake rate of the potential Cancer Pain drugs recently launched in the Cancer Pain market or expected to be launched in 2020-2034. The analysis covers the Cancer Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Cancer Pain Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Cancer Pain market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cancer Pain Pipeline Development Activities

The Cancer Pain report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cancer Pain key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Cancer Pain pipeline development activities @ Cancer Pain Therapies and Drugs

Cancer Pain Therapeutics Assessment

Major key companies are working proactively in the Cancer Pain Therapeutics market to develop novel therapies which will drive the Cancer Pain treatment markets in the upcoming years are Wex Pharma, Sorrento Therapeutics, Tetra Bio-Pharma, Abbvie, Novartis AG, Teva Pharmaceutical, Pfizer Inc, Amneal Pharmaceuticals, Aurobindo Pharma, Johnsons & Johnsons, GSK Plc, Sun Pharmaceutical, Cipla Inc, Ipsen Pharma, Sanofi, Boehringer Ingelheim, Alembic Pharmaceuticals, Lupin, Zydus Group, Apotex Inc, Aurobindo Pharma, Endo Pharmaceuticals plc, Orexo AB, Mundipharma International, Hisamitsu Pharmaceutical and others.

Learn more about the emerging Cancer Pain therapies & key companies @ Cancer Pain Clinical Trials and Updates

Cancer Pain Report Key Insights

1. Cancer Pain Patient Population

2. Cancer Pain Market Size and Trends

3. Key Cross Competition in the Cancer Pain Market

4. Cancer Pain Market Dynamics (Key Drivers and Barriers)

5. Cancer Pain Market Opportunities

6. Cancer Pain Therapeutic Approaches

7. Cancer Pain Pipeline Analysis

8. Cancer Pain Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cancer Pain Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Cancer Pain Competitive Intelligence Analysis

4. Cancer Pain Market Overview at a Glance

5. Cancer Pain Disease Background and Overview

6. Cancer Pain Patient Journey

7. Cancer Pain Epidemiology and Patient Population

8. Cancer Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Cancer Pain Unmet Needs

10. Key Endpoints of Cancer Pain Treatment

11. Cancer Pain Marketed Products

12. Cancer Pain Emerging Therapies

13. Cancer Pain Seven Major Market Analysis

14. Attribute Analysis

15. Cancer Pain Market Outlook (7 major markets)

16. Cancer Pain Access and Reimbursement Overview

17. KOL Views on the Cancer Pain Market

18. Cancer Pain Market Drivers

19. Cancer Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services